Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

First patient enrolled in Reata's Phase II trial of RTA 408 to treat radiation dermatitis By PBR Staff Writer
Reata Pharmaceuticals has enrolled the first patient in a Phase II dose-ranging trial of RTA 408 Lotion in breast cancer patients at risk for radiation dermatitis.
Contract Research & Services > Clinical Trials > News
Bayer, Onyx report results from Phase III breast cancer trial of sorafenib By PBR Staff Writer
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have released results from an investigational Phase III trial of sorafenib (Nexavar) tablets plus capecitabine in patients with advanced breast cancer.
Contract Research & Services > Clinical Trials > News Merck enrols first patient in Phase III trial of letermovir for prevention of CMV infection By PBR Staff Writer
Merck has enrolled first patient in a global Phase III clinical trial of letermovir (MK-8228), an investigational antiviral agent, for prevention of cytomegalovirus (CMV) infection in high-risk bone marrow transplant patients.
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
Biosceptre reports positive Phase I results for BIL-010t to treat Basal Cell Carcinoma
Biosceptre, the oncology company developing antibody products that target the nf-P2X7 receptor, has reported positive results from its Phase I trial to assess the safety and tolerability of BIL-010t (formerly known as BSCT (Anti-nf-P2X7) 10% Ointment), a topically administered, highly purified sheep antibody therapy, to treat Basal Cell Carcinoma (BCC).
Contract Research & Services > Clinical Trials > News
Antares starts dosing in Phase III QuickShot trial evaluating testosterone-deficient adult males
By PBR Staff Writer
US-based Antares Pharma has dosed first patient in a Phase III trial designed to evaluate the efficacy and safety of QuickShot Testosterone (QS T) administered subcutaneously once each week to testosterone-deficient adult males.
Contract Research & Services > Clinical Trials > News
Dipexium enrols first patient in Phase III trials of Locilex
By PBR Staff Writer
Dipexium Pharmaceuticals has enrolled first patient in the second of two pivotal Phase III clinical trials, called OneStep-1 and OneStep-2, evaluating its new, broad-spectrum, topical antibiotic peptide, Locilex (pexiganan cream 0.8%), to treat patients mild infections of diabetic foot ulcers, or Mild DFI.
Contract Research & Services > Clinical Trials > News
Synergy closes patient enrollment in Phase II trial of SP-333 in patients OIC
By PBR Staff Writer
US-based Synergy Pharmaceuticals has completed patient enrollment in its Phase II trial of SP-333, its next-generation uroguanylin analog, in patients with opioid-induced constipation (OIC).
Contract Research & Services > Clinical Trials > News
Rexahn provides update on Phase I Supinoxin trial in cancer patients with solid tumors
Rexahn Pharmaceuticals, a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, has announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin (RX-5902) in cancer patients with solid tumors.
Contract Research & Services > Clinical Trials > News
Janssen to start phase III trial of daratumumab in multiple myeloma in Q4 2014
By PBR Staff Writer
Genmab partner Janssen Biotech (Janssen) is planning to start a new phase III trial of daratumumab for the treatment of patients with multiple myeloma during the fourth quarter of 2014.
Contract Research & Services > Clinical Trials > News
Pfizer releases positive results from Phase III trial of BeneFIX to treat hemophilia B
By PBR Staff Writer
US-based Pfizer has released positive results from its Phase III trial comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX (Recombinant) 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B.
Contract Research & Services > Clinical Trials > News
Alkermes begins Phase I trial of ALKS 8700 to treat multiple sclerosis
By PBR Staff Writer
Ireland-based biopharmaceutical firm Alkermes has started a Phase I clinical trial of ALKS 8700, a novel monomethyl fumarate (MMF) molecule being developed for the treatment of multiple sclerosis (MS).
Contract Research & Services > Clinical Trials > News
Auspex begins pivotal Phase 2/3 clinical trial for SD-809 in Tardive Dyskinesia
Auspex Pharmaceuticals, a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, has announced the enrollment of the first two patients in a multi-center pivotal Phase 2/3 clinical trial of its investigational drug, SD-809 (deutetrabenazine), for the treatment of tardive dyskinesia (TD).
Contract Research & Services > Clinical Trials > News
BMS, Pfizer begin patient enrollment in Phase IV EMANATE trial of Eliquis
By PBR Staff Writer
Bristol-Myers Squibb (BMS) and Pfizer have started patient enrollment in a Phase IV clinical trial called EMANATE (Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnTicoagulation in subjEcts with NVAF) evaluating the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion.
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests

Buy the latest industry research online today!
Shire Plc : Pharmaceuticals & Healthcare - Company Profile, SWOT & Financial Report 03 October 2013 This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250